Albany, NY -- (SBWIRE) -- 08/05/2019 -- Chronic Lymphocytic Leukemia Market Insights, Epidemiology and Market Forecast-2028
1. Chronic Lymphocytic Leukemia represents 22–30% of all leukemia cases with a worldwide incidence projected to be between less than 1 and 5.5 per 100,000 patients.
2. Chronic lymphocytic leukemia new cases in 2018 are 20,940, which is about one-quarter of the new cases of leukemia.
3. In the UK, 63% of chronic lymphocytic leukemia cases were diagnosed in males, and 37% in females.
DelveInsight launched a new report on Chronic Lymphocytic Leukemia Market Insights, Epidemiology and Market Forecast-2028
Key benefits
1. Chronic Lymphocytic Leukemia market report covers a descriptive overview and comprehensive insight of the Chronic Lymphocytic Leukemia Epidemiology and Chronic Lymphocytic Leukemia market in the 7 MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
2. Chronic Lymphocytic Leukemia market report provides insights on the current and emerging therapies.
3. Chronic Lymphocytic Leukemia market report provides a global historical and forecasted market covering drug outreach in 7 MM.
4. Chronic Lymphocytic Leukemia market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Chronic Lymphocytic Leukemia market.
Request for sample pages
"Chronic lymphocytic leukemia is the most frequently diagnosed among people aged 65–74."
The available Chronic Lymphocytic Leukemia treatment options vary depending on the patients' age, disease risk group, and the displayed symptoms. The goal of Chronic Lymphocytic Leukemia treatment for the patient is the induction of remission and prolonging life while minimizing treatment?related adverse effects. There is an exception for the allogeneic hematopoietic stem cell transplantation (HSCT), none of Chronic Lymphocytic Leukemia current therapies is considered curative, but a subset of patients experiences long?term remissions.
Looking at Chronic Lymphocytic Leukemia treatment options, it has seen a significant evolution in the last decades. The initial chemotherapy with chlorambucil has mainly been replaced with more effective chemoimmunotherapy regimens including monoclonal antibodies (mAbs) targeting CD20 (rituximab [Rituxan], obinutuzumab [Gazyva], and ofatumumab [Arzerra]), and targeted therapy with the small?molecule inhibitor of Bruton's tyrosine kinase (BTK), ibrutinib (Imbruvica). Current standard?of?care for patients with relapsed or refractory Chronic Lymphocytic Leukemia is ibrutinib, the phosphatidylinositol 3?kinase (PI3K) inhibitor idelalisib (Zydelig) with rituximab, and the B cell lymphoma 2 (BCL?2) inhibitor venetoclax (Venclexta). The availability of these agents has changed results for patients with relapsed Chronic Lymphocytic Leukemia and adverse risk features, who had survival expectancies of less than one year in the past but can now achieve progression?free survival (PFS) in the range of 24 months or longer.
The United States holds the largest Chronic Lymphocytic Leukemia market size as compared to other countries. The significant factors driving Chronic Lymphocytic Leukemia market is the increasing population and the expansion in treatment patterns of relapsed/refractory Chronic Lymphocytic Leukemia.
Chronic Lymphocytic Leukemia market size is believed to experience modest growth during the forecast period due to the expected launch of novel therapies [2019?2028].
Drugs covered
1. Acalabrutinib
2. Zanubrutinib
3. Ublituximab
4. INVAC?1
And many others
The key players in Chronic Lymphocytic Leukemia market are:
1. Acerta Pharma
2. Beigene
3. TG Therapeutics
4. Invectys
And many others
Table of contents
1. Report Introduction
2. Chronic Lymphocytic Leukemia Market Overview at a Glance
3. Chronic Lymphocytic Leukemia Disease Background and Overview
4. Chronic Lymphocytic Leukemia Epidemiology and Patient Population
5. Chronic Lymphocytic Leukemia Country? Wise Epidemiology
5.1. United States
5.2. EU?5
5.2.1. Germany
5.2.2. France
5.2.3. Italy
5.2.4. Spain
5.2.5. United Kingdom
5.3. Japan
6. Chronic Lymphocytic Leukemia Treatment & Medical Practices
7. Chronic Lymphocytic Leukemia Marketed drugs
7.1. Imbruvica: AbbVie
7.2. Duvelisib: Verastem
7.3. Leukeran: GlaxoSmithKline
8. Chronic Lymphocytic Leukemia Emerging Therapies
8.1. Key Cross Competition
8.2. ACP?196: Acerta Pharma
8.3. BGB?3111: Beigene
8.4. TG?1101: TG Therapeutics
8.5. INVAC?1: Invectys
9. Chronic Lymphocytic Leukemia Market Size
10. 7MM Chronic Lymphocytic Leukemia Country?Wise Market Analysis
10.1.United States
10.2.Germany
10.3. France
10.4. Italy
10.5. Spain
10.6.United Kingdom
10.7.Japan
11. Chronic Lymphocytic Leukemia Report Methodology
12. DelveInsight Capabilities
13. Disclaimer
14. About DelveInsight
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.
Contact us:
Shruti Thakur
info@delveinsight.com
+919650213330
SOURCE DelveInsight